Supplementary plain language summary: Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database

figure

posted on 2025-02-12, 15:47 authored by Aliza B Ben-Zacharia, Jenny Feng, Brandon P Moss, Nicholas Belviso, Yu Zhang, Filipe Branco, Jason P Mendoza, James B. Lewin, Sarah M. England

These are peer-reviewed supplementary materials for the article 'Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database' published in the Journal of Comparative Effectiveness Research.

Plain language summary: A study looking at people living with multiple sclerosis who switched from treatment with anti-CD20s to fumarates

How to pronounce
Why was this study done?
What did researchers want to find out?
What were the findings from this study?
What were the main conclusions from this study?
Who funded this study?

Funding

Biogen (MA, USA) sponsored this study and provided funding for medical writing and editorial support in the development of this paper.

History

Usage metrics

Keywords

anti-CD20 monoclonal antibodies de-escalation fumarates healthcare costs healthcare encounters multiple sclerosis switching

Licence

CC BY-NC-ND 4.0